# US 2023/0416373 A1 · Biphasic subcutaneous dosing regimens for anti-vla-4 antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0416373 A1
- Document ID: US20230416373A1
- Status: Published application
- Kind: A1
- Application number: 18/036,620
- Filed: 2021-11-12
- Published: 2023-12-28
- Earliest claimed: 2020-11-14
- Assignees: Biogen MA Inc.
- Applicants: Biogen Ma Inc.
- Inventors: Yuan ZHAO; Himanshu NAIK; Nolan CAMPBELL
- Web page: https://patentgrep.com/patent/US20230416373A1

## CPC

- C07K 16/2842: {against integrin beta1-subunit-containing molecules, e.g. CD29, CD49}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are biphasic dosing protocols for natalizumab therapy comprising both standard and extended interval dosing and subcutaneous administration.

## Claims

### Claim 1

A method of reducing pathological inflammation in a patient in need thereof comprising administering a therapeutically effective amount of an anti-VLA-4 antibody to the patient in a biphasic dosing regimen, wherein the biphasic regimen comprises an induction phase comprising administration of the anti-VLA-4 antibody once a month for 10 to 14 months, preferably at least 12 months, followed by a chronic phase comprising administration of the anti-VLA-4 therapy once every 5, 6, 7 or 8 weeks, preferably wherein at least one phase of the biphasic protocol comprises subcutaneous (SC) administration.

### Claim 2

A method of reducing progressive multifocal leukoencephalopathy (PML) in a patient known or suspected of suffering from multiple sclerosis, comprising administering a therapeutically effective amount of an anti-VLA-4 antibody to the patient in a biphasic dosing regimen, wherein the biphasic regimen comprises an induction phase comprising administration of the anti-VLA-4 antibody once a month for 10 to 14 months, preferably at least 12 months, followed by a chronic phase comprising administration of the anti-VLA-4 therapy once every 5, 6, 7 or 8 weeks, preferably wherein at least one phase of the biphasic protocol comprises subcutaneous (SC) administration.

### Claim 3 (depends on 1)

The method of claim 1, wherein the pathological inflammation is caused by multiple sclerosis, and the therapeutically effective amount is sufficient to relieve symptoms of multiple sclerosis.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the anti-VLA-4 antibody is natalizumab.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein administration during the induction phase is intravenous (IV) or subcutaneous (SC), preferably SC.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein administration during the chronic phase is IV or SC, preferably SC.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein both phases of the regimen comprise SC administration.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the therapeutically effective amount administered during the induction phase and the chronic phase are the same; preferably wherein the therapeutically effective amount is 300 mg.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

The method according to any one of claims 1-7, wherein the therapeutically effective amount administered SC during the chronic phase is about 300 mg, about 350 mg, about 400 mg, about 450 mg, or about 500 mg, more preferably about 300 mg, still more preferably 300 mg.

### Claim 10

A method of administering natalizumab to a patient in need thereof based on a biphasic dosing regimen, the method comprising administering the natalizumab therapy subcutaneously on an SID schedule for an induction phase of at least 12 months, and then administering the natalizumab therapy on an EID schedule of at least 6-week intervals chronically thereafter, wherein one or both, and preferably both, treatment phases comprise SC administration.

### Claim 11 (depends on 10)

The method of claim 10, wherein the therapeutically effective amount administered during the induction phase and the chronic phase are the same; preferably wherein the therapeutically effective amount is 300 mg.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the therapeutically effective amount administered SC during the chronic phase is about 300 mg, about 350 mg, about 400 mg, about 450 mg, or about 500 mg, more preferably about 300 mg, still more preferably 300 mg.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method according to any one of claims 1-12, further comprising a) measuring a soluble molecule in a first biological sample obtained from the patient during the induction phase, wherein the soluble molecule is serum vascular cell adhesion molecule (sVCAM) and/or neurofilament light chain (Nf-L); b) measuring the sVCAM and/or Nf-L in a second biological sample obtained from the individual during the chronic phase; c) determining whether there is an increase in the levels of the sVCAM and/or Nf-L above predetermined levels between the first and second biological samples, and d) in the event of an increase above said predetermined levels reverting said patient to an SID schedule or increasing the dose frequency of the EID schedule.

### Claim 14

A method for determining and/or monitoring the efficacy of a biphasic dosing protocol for natalizumab having an induction phase comprising an SID schedule and a chronic phase comprising an EID schedule in a patient in need thereof, the method comprising a) measuring a soluble molecule in a first biological sample obtained from the patient during the induction phase, wherein the soluble molecule is sVCAM and/or Nf-L; b) measuring the sVCAM and/or Nf-L in a second biological sample obtained from the individual during the chronic phase; c) determining whether there is an increase in the levels of the sVCAM and/or Nf-L above predetermined thresholds between the first and second samples, and d) in the event of an increase above one or both predetermined thresholds reverting said patient to an SID schedule or increasing the dose frequency of the EID schedule.
